Instil Bio is involved in the development of novel cell therapies for cancer treatment. The company focuses on advancing its clinical pipelines.

Instil Bio

IPhone / Mobile Compatible

Viewport Meta

Domain Not Resolving

Google Tag Manager

HSTS

WordPress

Font Awesome

DNSSEC

Organization Schema

Sitelinks Search Box

Chief Executive Officer

Jaime Walkowiak

Chief Scientific Officer

Mark Dudley

Legal

Merritt Quigley

Chief Medical Officer

Zachary Roberts

Vice President - Head of Regulatory

Alex Babayan

VP, Global Head of IT at Instil Bio

Christophe Suchet

Vice President, Process Development & Manufacturing Operations

Faraz Siddiqui

VP of Engineering, Facilities, and Validation

Igor Segal

Vice President, Customer Engagement

Lisa Wynja

Head of Tech Transfer and Process Validation

Matt Romeo

Bronson Crouch

Chairman & CEO

Vijay Chiruvolu

Chief Technical Officer

Sandeep Laumas

Chief Financial Officer

Robert Hawkins

Chief Strategy Advisor / Founder

Amanda Longden

Senior Human Resources Manager

Tom Ramos

Senior Scientist

Companies With More Than $1M in Revenue (Top 10K)

Texas Companies With More Than 50 Employees (Top 10K)

Life Science Companies With Less Than $50M in Revenue

United States Public Companies With More Than $10M in Revenue

Instil Bio is a cell therapy company developing tumor infiltrating lymphocytes for the treatment of solid tumor cancers. It is advancing its proprietary manufacturing expertise, technology, and data into clinical trials, including a planned registrational study with its candidate and the first-in-human study of its next-generation engineered TIL.

Series C - Instil Bio

Series B - Instil Bio

Series A - Instil Bio

Dallas

Texas

United States

North America

Instil Bio reports Q2 EPS ($2.29), two estimates ($2.98)

Instil Bio stock gains on licensing deal (NASDAQ:TIL)

Instil Bio Shares Surge Following Rental Agreement with AstraZeneca

Instil Bio inks 15-year lease with AstraZeneca

Instil Bio reelects board members, ratifies auditor By Investing.com

Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Canada

Greenland

Germany

Europe

India

Asia

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.

Instil Bio, Inc.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Oct 16, 2024 5:38 AM	70fb00a0
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 16, 2024 5:38 AM	d3a83c32
crunchbase trigger	general	Nov 4, 2024 10:53 AM	68059670
crunchbase profile	general	Nov 5, 2024 5:01 AM	96ec16b2
li profile	general
translate crunchbase fundingrounds	general	Nov 5, 2024 6:02 AM	b4362584
peers	general	Oct 16, 2024 5:38 AM	3444e75e
news basic	general	Oct 16, 2024 5:38 AM	0dd2e5eb
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:INSTILBIO

Instil Bio

Last Close

24.76

22/11 21:00

Market Cap

65.10M

Beta: -

Volume Today

91.17K

Avg: -